THTadayoshi Hashimoto

Tadayoshi Hashimoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tadayoshi Hashimoto has a total of 294 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    High AXL Expression and Stromal–Angiogenic Immune Phenotypes in Upper Gastrointestinal Cancers

    by Kyosuke Seguchi, Tadayoshi Hashimoto, Takao Fujisawa, Akitaka Makiyama, Toshihiro Kudo, Kentaro Yamazaki, Koushiro Ohtsubo, Taroh Satoh, Chigusa Morizane, Shogen Boku, et al.

    AXL, a receptor tyrosine kinase, has been implicated in epithelial–mesenchymal transition, angiogenesis, immune evasion, and therapeutic resistance, but its relevance in upper gastrointestinal cancers remains incompletely defined. We analyzed 337 patients with advanced gastric ( n = 287) or esophageal ( n = 50) cancer enrolled in SCRUM‐Japan MONSTAR‐SCREEN‐2, whose tumors were profiled by whole‐exome and whole‐transcriptome sequencing. Patients were classified as AXL ‐high ( n = 169) or AXL ‐low ( n = 168) using cancer type‐specific median transcripts‐per‐million cutoffs. Median follow‐up was 14.1 months. AXL ‐high tumors were associated with shorter overall survival than AXL ‐low tumors (median, 12.9 versus 17.1 months; hazard ratio, 1.58; 95% confidence interval, 1.17–2.14; p = 0.003), consistently in gastric (hazard ratio, 1.47; p = 0.020) and esophageal (hazard ratio, 2.46; p = 0.027) cancer. This association persisted after adjustment for cancer type, age, sex, number of metastatic sites, microsatellite instability status, and tumor mutational burden (hazard ratio, 1.59; 95% confidence interval, 1.14–2.22; p = 0.007). Among microsatellite stable patients treated with immune checkpoint blockade, AXL expression was not associated with progression‐free survival (hazard ratio, 0.83; 95% confidence interval, 0.61–1.14; p = 0.255). AXL ‐high tumors showed stromal and vascular expansion, regulatory T‐cell enrichment, higher expression of fibroblast growth factor receptor 1, vascular endothelial growth factor receptors 1–3, and MET , and enrichment of epithelial–mesenchymal transition, angiogenesis, and transforming growth factor beta signaling. High AXL expression identifies a poor‐prognosis stromal‐angiogenic phenotype in upper gastrointestinal cancers and warrants prospective validation as a prognostic, rather than predictive, biomarker. Trial Registration: UMIN Clinical Trials Registry, UMIN000043899

  • Longitudinal remodeling of the tumor-immune microenvironment during regorafenib, nivolumab, and chemotherapy in advanced gastric cancer

    by Kota Itahashi, Akihito Kawazoe, Tadayoshi Hashimoto, Yue Yan, Takuma Irie, Hiromi Ono, Hitomi Tamura, Kyoko Hongo, Takashi Ikeno, Masashi Wakabayashi, et al.

    Previous studies combining the multikinase inhibitor regorafenib with a PD-1 inhibitor showed promising activity in gastric cancer. We conducted a phase 1b/2 trial (NCT05394740) of first-line regorafenib, nivolumab, and chemotherapy in 30 patients with mismatch repair–proficient gastric cancer and investigated its impact on the tumor microenvironment. The primary end point was met; 22 of 30 patients showed objective tumor response (73%; 80% confidence interval, 60.3 to 83.8). Single-cell RNA and T cell receptor sequencing were performed on biopsy samples at baseline, during treatment, and at disease progression. The combination treatment increased tumor antigen–reactive CD8 + T cells and M1-like proinflammatory macrophages and decreased immunosuppressive and tumor-promoting populations, including activated CCR8 + regulatory T cells, LRRC15 + cancer-associated fibroblasts (CAFs), RGS5 + pericytes, and APLN + tip cells. At progression, LRRC15 + CAFs and APLN + tip cells remained reduced, activated CCR8 + regulatory T cells reexpanded, and additional treatment-resistant subsets emerged, including APOC1 + lipid-associated macrophages. In murine models of acquired resistance, therapeutic targeting of these suppressive immune cell populations with antibodies against CCR8 or TREM2 in combination with PD-1 blockade restored antitumor immunity. These findings demonstrate dynamic remodeling of the tumor microenvironment and suggest potential therapeutic targets.

  • Open Access

    Longitudinal ctDNA profiling to guide anti-EGFR rechallenge in metastatic colorectal cancer: a prospective single-arm phase II trial

    by Yoshinori Kagawa, Daisuke Kotani, Hiroya Taniguchi, Tadayoshi Hashimoto, Hideaki Bando, Naoki Takahashi, Tetsuya Hamaguchi, Akiyoshi Kanazawa, Takeshi Kato, Koji Ando, et al.

  • Open Access

    Clinical significance of WES-defined ERBB2 amplification in resectable colorectal cancer

    by Kazuki Kishi, Atsushi Hamabe, Yusuke Suwa, Naoya Akazawa, Keiji Hirata, Masataka Ikeda, Mitsuru Yokota, Kentaro Kato, Masahito Kotaka, Yujiro Nishizawa, et al.

    Background: HER2 amplification is demonstrated to influence response to therapy and outcomes in metastatic colorectal cancer (mCRC), but its role in resectable CRC remains unclear. This study investigated the prognostic impact of WES-defined ERBB2 amplification and its association with adjuvant chemotherapy (ACT) efficacy and circulating tumor DNA (ctDNA) in resectable CRC. Methods: Data from 3607 patients with resectable CRC from the GALAXY study were analyzed. HER2 amplification was defined using ERBB2 copy number alterations based on whole exome sequencing of tumor specimens. We analyzed disease-free survival (DFS) in WES-defined ERBB2 amplified CRC, evaluating ACT benefit and the correlation between ERBB2 copy number and ctDNA status. Results: No significant difference in DFS was observed between those with and without WES-defined ERBB2 amplification in a univariate ( P = 0.0659) or a multivariate analysis ( P = 0.2300). Among patients with pathological stage III, ACT was associated with improved DFS in the non-amplified subgroup (HR 0.67, P = 0.0002), particularly in the subgroup of patients with early post-operative (2–10 weeks following surgical resection) ctDNA-positivity (HR 0.27, P < 0.0001), whereas no clear association was detected in the small amplified subgroup; however, the ACT-by- ERBB2 amplification interaction was not statistically significant. While WES-defined ERBB2 amplification correlated with higher early post-operative ctDNA positivity ( P = 0.0486), ERBB2 copy number did not associate with recurrence or levels. However, early post-operative ctDNA positivity strongly predicted poor DFS in patients with WES-defined ERBB2 amplification (HR 15.26, P < 0.0001). Conclusions: WES-defined ERBB2 amplification was not identified as a significant adverse prognostic factor in resectable CRC, unlike early post-operative ctDNA status. The limited number of amplified cases precluded a reliable assessment of whether WES-defined ERBB2 amplification modifies the association between ACT and DFS.

  • Open Access

    AI-integrated multi-omics platform to revolutionize anti-metastatic therapy development through circulating tumor cell profiling: SCRUM-MONSTAR-CTC

    by Tadayoshi Hashimoto, Taro Shibuki, Takao Fujisawa, Shogen Boku, Mizuho Kikuchi, Atsuko Shimizu, Tomoe Murakami, Yasutoshi Sakamoto, Izumi Miki, Naoko Iida, et al.

    Background: Metastatic disease remains the leading cause of cancer-related death, yet most precision oncology strategies still emphasize profiling primary tumors and tracking cell-free tumor DNA (ctDNA). Although ctDNA has transformed genomic profiling, molecular residual disease monitoring, and early cancer detection, it cannot directly capture viable tumor cell states, phenotypic plasticity, or functional adaptations that drive metastatic spread. We propose that the next phase of precision oncology should integrate the cellular dimension of metastasis through systematic circulating tumor cell (CTC) profiling. Methods: The SCRUM-MONSTAR platform, one of the largest pan-cancer molecular profiling initiatives in Japan, offers an exceptional foundation for this transition through its nationwide infrastructure for multi-omics analysis, longitudinal biospecimen collection, and artificial intelligence-enabled clinical interpretation. By combining matched tissue profiling, serial ctDNA analysis, single-cell CTC transcriptomics, metabolomics, and organoid- and mouse-based functional modeling, SCRUM-MONSTAR-CTC could evolve into a translational ecosystem for anti-metastatic drug discovery. Within this framework, we highlight adherent-to-suspension transition (AST) as one representative, experimentally tractable plasticity program that enables tumor cells to survive in circulation and subsequently colonize distant organs. Discussion: We envision that identifying and therapeutically targeting AST-related and other metastatic plasticity programs across tumor types will provide a path toward clinically actionable anti-metastatic therapies. More broadly, this framework could enable the identification of metastatic vulnerabilities, the development of biomarker-guided anti-metastatic trials, and the reverse translation of patient-derived discoveries into early-phase clinical testing. Precision oncology must move beyond cataloging tumor genomes and begin targeting metastasis as a dynamic biological process. Trial Registration: UMIN000056873, approved by the Institutional Review Board of the National Cancer Center Hospital East.

  • Open Access

    Supplementary Table 3 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

    by Tadayoshi Hashimoto, Yoshiaki Nakamura, Takao Fujisawa, Mitsuho Imai, Taro Shibuki, Naoko Iida, Hiroshi Ozaki, Norio Nonomura, Chigusa Morizane, Hiroji Iwata, et al.

    Cox multivariate analysis of overall survival

  • Open Access

    Supplementary Figure 4 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

    by Tadayoshi Hashimoto, Yoshiaki Nakamura, Takao Fujisawa, Mitsuho Imai, Taro Shibuki, Naoko Iida, Hiroshi Ozaki, Norio Nonomura, Chigusa Morizane, Hiroji Iwata, et al.

    Concept of no-placebo initiative

  • Open Access

    Supplementary Figure 3 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

    by Tadayoshi Hashimoto, Yoshiaki Nakamura, Takao Fujisawa, Mitsuho Imai, Taro Shibuki, Naoko Iida, Hiroshi Ozaki, Norio Nonomura, Chigusa Morizane, Hiroji Iwata, et al.

    Design of the whole transcriptome sequencing–based clinical trial platform in MONSTAR-SCREEN-3

  • Open Access

    Supplementary Figure 1 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

    by Tadayoshi Hashimoto, Yoshiaki Nakamura, Takao Fujisawa, Mitsuho Imai, Taro Shibuki, Naoko Iida, Hiroshi Ozaki, Norio Nonomura, Chigusa Morizane, Hiroji Iwata, et al.

    Conceptual framework for virtual sequencing using deep learning.

  • Open Access

    Supplementary Table 1 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

    by Tadayoshi Hashimoto, Yoshiaki Nakamura, Takao Fujisawa, Mitsuho Imai, Taro Shibuki, Naoko Iida, Hiroshi Ozaki, Norio Nonomura, Chigusa Morizane, Hiroji Iwata, et al.

    List of regulatory approvals for targeted therapies and associated clinical trials in SCRUM-Japan MONSTAR-SCREEN project